DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)

Phase

2/3

Condition

Liver Disorders

Hepatitis B

Hepatitis

Treatment

N/A

Clinical Study ID

NCT02555943

H&H_DASCO

Ages 18-70
All Genders

Study Summary

This is a prospective study to determine the incidence, morbidity, mortality and predisposing factors for the reactivation of hepatitis B virus replication during direct anti-HCV treatment of HCV/HBV co-infection patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

HCV RNA positive,
HBsAg positive with detectable or undetectable HBV DNA,
Receiving pan oral direct-acting anti-HCV regimen

Exclusion

Exclusion Criteria:

Pregnant or nursing female or male with pregnant female partner;
HIV infection;
Hematologic or biochemical parameters at Screening outside the protocol- specifiedrequirements;
Active or recent history (≤ 1 year) of drug or alcohol abuse;
History or current evidence of any condition, therapy, laboratory abnormality or othercircumstance that might confound the results of the study, or interfere with thesubject's participation for the full duration of the study, such that it is not in thebest interest of the subject to participate.

Study Design

February 01, 2015

August 31, 2021

Study Description

Patients who receive direct-acting anti-HCV treatment will be prospectively studied during 2-year period. All patients have HCV/HBV co-infection.

The inclusion/exclusion criteria and the follow up plan will be listed in following part.

Connect with a study center

Humanity and Health GI and Liver Centre
Hong Kong, Hong Kong 00852
China
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.